<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098575</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0198</org_study_id>
    <nct_id>NCT04098575</nct_id>
  </id_info>
  <brief_title>A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes</brief_title>
  <acronym>EDCOS</acronym>
  <official_title>Treatment of T2DM Patients in Germany Receiving Empagliflozin: A Retrospective RWE Study Description of Treatment and Population Characteristics of Type 2 Diabetic Patients in Germany Receiving Empagliflozin: A Retrospective Real-World Evidence (RWE) Study Based on German Registries DPV&amp;DIVE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM)
      receiving Empagliflozin, comparing the characteristics of patients starting Empa-gliflozin in
      three time intervals
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of previous occurance of cardiovascular comorbidities</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Myocardial infarction (MI), Stroke, Coronary artery disease (CAD), Peripheral artery disease (PAD), CHF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Diabetes complications</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Neuropathy, Nephropathy / Renal function (eGFR, micro-/ macroalbuminuria), Diabetic foot syndrome, Retinopathy (background and proliferative)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Antidiabetic and cardiovascular co-medication</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with age</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>&lt;65; 65 - &lt;75; 75 - 80 , &gt;80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics: gender</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics: Weight</measure>
    <time_frame>Uop to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics: height</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics: HbA1c</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of diabetes (Time Since Diagnosis)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with previous glucose-lowering treatmen</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with 10mg and 25mg dosage of empagliflozin</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects participated in Disease Management Programme (DMP) Type 2 Diabetes (from DPV registry)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>from DPV registry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with hospitalizations</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>from DPV registry</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">7900</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patients receiving Empagliflozin until mid Sep 2015</arm_group_label>
    <description>Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients receiving Empagliflozin until CV Label Change time</arm_group_label>
    <description>Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients receiving Empagliflozin until last available data cut</arm_group_label>
    <description>Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>drug</description>
    <arm_group_label>Patients receiving Empagliflozin until CV Label Change time</arm_group_label>
    <arm_group_label>Patients receiving Empagliflozin until last available data cut</arm_group_label>
    <arm_group_label>Patients receiving Empagliflozin until mid Sep 2015</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Diabetes Mellitus, Type 2, treated with Empagliflozin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least two outpatient T2DM diagnoses (ICD E11.-) in two different quarters and/or at
             least one inpatient T2DM diagnosis (ICD E11)

          -  At least one prescription of an empagliflozin-containing antidiabetic drug: Jardiance®
             (Empagliflozin, ATC A10BK03, former A10BX12) or Synjardy® (Empagliflozin/ Met¬for¬min,
             ATC A10BD20)

        Exclusion Criteria:

          -  Any diagnosis of T1DM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diabetes Agenda 2010 GmbH</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
Studies in products where Boehringer Ingelheim is not the license holder
Studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials
Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
Requestors can use the following link http://trials.boehringer-ingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

